← Leaderboards
James M O'Donnell
University Of Tennessee Health Sci Ctr
$6,936,708
Attributed
$7,745,712
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2005–21$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$7,745,712 · 7
By mechanism
R01$4,458,458 · 2
RC1$951,629 · 1
T32$841,122 · 1
K02$628,469 · 1
R43$499,784 · 1
R56$366,250 · 1
Top collaborators
- Chang-Guo Zhan2 shared
- Fu Du1 shared
- Wei Wang1 shared
Most similar at University Of Tennessee Health Sci Ctr
Same institution · by research overlap
- Polly A Hofmann$2,013,232
- Robert Walker$101,157
- Suleiman Wakim Bahouth$1,473,800
Others in their field
Top investigators on “Psychopharmacology”
- Joseph S Takahashi · University Of Chicago$22,466,198
- George Bigelow · Johns Hopkins University$10,797,907
- Kathryn A. Cunningham · University Of Texas Med Br Galveston$9,871,445
- John H Krystal · Yale University$9,702,045
- Scott E Lukas · Mc Lean Hospital (Belmont, Ma)$8,906,814
- Steven H Ferris · New York University School Of Medicine$8,112,879
Research focus
PsychopharmacologyPhosphodiesterase InhibitorsLaboratory RatAntidepressantsBehavioralBehaviorEnzyme ActivityBeta Adrenergic ReceptorAdenylate CyclaseDopamine ReceptorPharmacokineticsCyclic AmpNorepinephrineDrug InteractionsNeurochemistryMicrodialysisTissue /Cell CultureInhibitor/AntagonistDesipramineDosagePharmaceutical PreparationsEthologyAntisense Nucleic AcidDrug Administration Rate /Duration
Grant awards (35)
Discovery of PDE2A inhibitors to treat memory deficits in mild cognitive impairment and Alzheimer's disease$499,784
R43 · FY2021 · AG
Research Training Program in the Behavioral and Biomedical Sciences$104,386
T32 · FY2012 · GM · contact PI
Research Training Program in the Behavioral and Biomedical Sciences$157,184
T32 · FY2011 · GM · contact PI
Phosphodiesterase-2 and Mood Disorders: Target Validation and Drug Discovery$468,313
RC1 · FY2010 · MH · contact PI
Research Training Program in the Behavioral and Biomedical Sciences$155,370
T32 · FY2010 · GM · contact PI
Phosphodiesterase-2 and Mood Disorders: Target Validation and Drug Discovery$483,316
RC1 · FY2009 · MH · contact PI
Monoamine Transporter Regulation and Antidepressant Activity$366,250
R56 · FY2009 · MH · contact PI
Research Training Program in the Behavioral and Biomedical Sciences$154,488
T32 · FY2009 · GM · contact PI
Research Training Program in the Behavioral and Biomedical Sciences$154,488
T32 · FY2009 · GM · contact PI
Central Beta Adrenergic Receptors$312,545
R01 · FY2008 · MH · contact PI
Research Training Program in the Behavioral and Biomedical Sciences$115,206
T32 · FY2008 · GM · contact PI
Neuropsychopharmacology of Cyclic AMP PDE Inhibitors$347,271
R01 · FY2007 · MH · contact PI
Central Beta Adrenergic Receptors$312,545
R01 · FY2007 · MH · contact PI
Neuropsychopharmacology of Cyclic AMP PDE Inhibitors$357,643
R01 · FY2006 · MH · contact PI
Central Beta Adrenergic Receptors$321,880
R01 · FY2006 · MH · contact PI
Neuropsychopharmacology of Cyclic AMP PDE Inhibitors$366,055
R01 · FY2005 · MH
Central Beta Adrenergic Receptors$245,834
R01 · FY2005 · MH
Central Beta Adrenergic Receptors$49,815
R01 · FY2005 · MH
Neuropsychopharmacology of Cyclic AMP PDE Inhibitors$198
R01 · FY2005 · MH
Neuropsychopharmacology of Cyclic AMP PDE Inhibitors$286,000
R01 · FY2004 · MH
Central Beta Adrenergic Receptors$262,800
R01 · FY2004 · MH
NOVEL MECHANISMS OF ANTIDEPRESSANT ACTIVITY$133,089
K02 · FY2004 · MH
Neuropsychopharmacology of Cyclic AMP PDE Inhibitors$286,000
R01 · FY2003 · MH
NOVEL MECHANISMS OF ANTIDEPRESSANT ACTIVITY$132,044
K02 · FY2003 · MH
NEUROPSYCHOPHARMACOLOGY OF CYCLIC AMP PDE INHIBITORS$232,187
R01 · FY2002 · MH
CENTRAL BETA ADRENERGIC RECEPTORS$213,000
R01 · FY2002 · MH
NOVEL MECHANISMS OF ANTIDEPRESSANT ACTIVITY$131,029
K02 · FY2002 · MH
NEUROPSYCHOPHARMACOLOGY OF CYCLIC AMP PDE INHIBITORS$223,258
R01 · FY2001 · MH
CENTRAL BETA ADRENERGIC RECEPTORS$213,000
R01 · FY2001 · MH
NOVEL MECHANISMS OF ANTIDEPRESSANT ACTIVITY$130,044
K02 · FY2001 · MH
CENTRAL BETA ADRENERGIC RECEPTORS$209,220
R01 · FY2000 · MH
NEUROPSYCHOPHARMACOLOGY OF CYCLIC AMP PDE INHIBITORS$197,207
R01 · FY2000 · MH
NOVEL MECHANISMS OF ANTIDEPRESSANT ACTIVITY$69,863
K02 · FY2000 · MH
NOVEL MECHANISMS OF ANTIDEPRESSANT ACTIVITY$32,400
K02 · FY2000 · MH
NEUROPSYCHOPHARMACOLOGY OF CYCLIC AMP PDE INHIBITORS$22,000
R01 · FY2000 · MH